HYDROMORPHON
Fabry's Disease
SanofiSmall moleculePhase 4 / ApprovedActive
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
9 Active assets in the Fabry's Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Loratadine Sanofi | Phase 4 | BB |
Fexofenadine Sanofi | Phase 4 | BB |
Montelukast Sanofi | Phase 4 | BB |
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Sanofi | Phase 4 | BB |
FENTANYL Sanofi | Phase 4 | BB |
View all 9 →
Same molecule, other indications
HYDROMORPHON is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →